First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

Debbie Robbrecht, Christiane Jungels, Morten Mau Sorensen, Iben Spanggaard, Ferry Eskens, Signe Ø Fretland, Tormod Kyrre Guren, Philippe Aftimos, David Liberg, Christer Svedman, Lars Thorsson, Neeltje Steeghs, Ahmad Awada

Fingerprint

Dive into the research topics of 'First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours'. Together they form a unique fingerprint.

Medicine & Life Sciences